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Due to the tremendous increase in our understanding of the cancer
process and cause, development of drugs to selectively interfere
with and inhibit tumour growth has now entered a new and excit-
ing era of the target orientated approach. Drugs are now being
developed against speciﬁc proteins involved in cancer cell growth
that have been uncovered over the last 10 years or so. These differ-
ences cover all areas of cancer biology, from cell signalling
pathways to tumour hypoxia and from angiogenesis to cell death
pathways. It therefore follows that to develop drugs that interfere
with these complex pathways, a comprehensive knowledge of the
cancer process is needed by today’s cancer researcher. This book
gives a very comprehensive overview of the whole of the anticancer
drug development process today, from chemical synthesis to the
clinic.
The book begins with a brief chapter on the history of
chemotherapy describing the problems of today’s anticancer drugs,
the lack of speciﬁcity or low therapeutic index. Individual sections
on speciﬁc areas follow, where the emphasis is on uncovering new
targets for therapeutic interference. These include the cell cycle,
signal transduction pathways and apoptosis. Not only are these
detailed and up-to-date reviews of the topic, but highlight areas
of possible therapeutic intervention throughout the text, including
compounds that are already known to act on these areas, very
useful for those not familiar with the ﬁeld. Each chapter concludes
with strategies for future drug development.
Attempts at inhibiting the cancer metastatic process have been
high proﬁle recently with the MMP inhibitors, Batimastat and
Marimastat, entering the clinic. Cancer metastasis is a complex
process, and this chapter not only gives an overview of the subject
but also describes in some detail the thinking behind the design of
existing and future MMP inhibitors.
Drug resistance pathways have long been an area of interest for
therapeutic intervention and these are brought up-to-date with our
current understanding of P-glycoprotein, NF-kB and the potential
role of tumour physiology in drug resistance. Anti-angiogenic
drugs and antivascular agents are not quite the same but have been
grouped to cover all aspects of tumour vasculature as a target. Here
we see slight overlap with other chapters, and indeed the editors do
comment on the overlap between chapters as each chapter is writ-
ten by independent authors. This overlap is inevitable (but
minimal), as tumour vasculature and angiogenesis is bound to
overlap with MMP expression and inhibition which is bound to
overlap with cell signalling, and so on. The GDEPT concept is
dependent on the activation of prodrugs at the tumour site. Several
useful enzyme-prodrugs systems are covered here as well as the
latest antigenic targets available for ADEPT. These are two concepts
that have shown promise preclinically but are still under develop-
ment in the clinic.
The drug discovery process is still a mixture of random screening
and rational drug design. There follows three chemistry based chap-
ters on drug design. Rational drug design and organic synthesis
(including combinatorial chemistry) with concluding remarks
which give pointers as to the future direction of the ﬁeld.
Natural products of course have had a major role to play in cancer
chemotherapy over the years. This chapter is written by chemists
who have the enviable job of travelling the world looking for
natural products with novel mechanisms of action. Here bryostatin
is used as an example to include details of structural modiﬁcation
and in vitro evaluation. Other natural products are certain to have
their inﬂuence on cancer drug development for some time to come.
Some of the technological advances over recent years would
have been unimaginable not too long ago. We are now in the
era described as post genomic drug discovery. Not only has the
technology advanced at an impressive rate but so has the informa-
tion gained from these technologies. Microarray analysis, genomics
and proteomics provide gigantic amounts of data for the cancer
researcher. These technologies have now been matched in the drug
discovery process by high throughput screening techniques. This
chapter brings together the previous 13 by describing the drug
screening processes itself, including the roles and values of target
identiﬁcation, target validation and combinatorial chemistry in
the drug discovery and development process.
The majority of reviews on drug development were dominated
by the NCI screening technologies. It is not really possible to
publish a review on anticancer drug development without includ-
ing the NCI screen, but the chapter on tumour cell cultures in
drug development takes a slightly different angle. The NCI screen
is covered in some detail but so are useful sections on three-dimen-
sional cultures and drug diffusion assays. Three-dimensional
cultures of characterised cell lines take in vitro drug screening a
step closer to the clinical situation. It is appropriate then to follow
this chapter with one on animal screening systems. Based primarily
on the experiences of those in Freiburg, who probably have one of
the largest animals screening facilities in Europe. With over 350
tumours all characterised for target expression, the emphasis is
placed on the characterisation of the tumours and clinical relevance
of the tumour models in mice. There is also an overview of these
facilities in Freiburg.
Extensive preclinical pharmacological and toxicological studies
prior to clinical trial are essential, not only to gain a thorough
understanding of the compounds pharmacology but also to aid
in the difﬁcult decision of which starting dose to use in the patient.
Extrapolation of animal data to humans is discussed in some detail,
comparing the relevance of preclinical information from mouse,
rat, dog and monkey. Preclinical data from six compounds that
have entered the clinic is used as an example, and the authors
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their prediction of human MTD (maximum tolerated dose) and
DLT (dose limiting toxicities).
This detailed preclinical data can then be used to optimize the
design of the clinical trials. This account explains in some detail
how a clear understanding of a drugs pharmacology can lead to
improved clinical use. A greater understanding of these pharma-
cokinetic-pharmacodynamic relationships has led to optimization
of the administration and delivery of new agents in Phase I
trials.
A major new development in clinical trial design is the ability to
measure the distribution and, to a certain extent, the pharmacody-
namic effect of these new agents in a non-invasive manner. PET
(positron emission tomography) has a whole chapter dedicated
to the technique and it is clear the power of the technique will
inﬂuence the design of future clinical trials. PET can now be used
for pharmacokinetic analysis with examples, for 5-FU and temozo-
lomide given. It can be used for pharmacodynamic studies, for
example drug receptor interactions and cellular proliferation, even
detecting apoptotic cells in situ.
The concluding chapter discusses trials of the newly emerging
mechanistic drugs. It describes trial design for the compounds such
as copolymers, intended to take advantage of the leaky vasculature
of tumours, and signal transduction inhibitors where it is now
necessary to build in pharmacodynamic endpoints, showing target
inhibition/activation, into clinical trials alongside the currently
established pharmacokinetic monitoring.
In summary, this is a really extensive and comprehensive book
on the drug development process. It has detailed chapters on
potential targets, the drug design process, the drug screening
process and the design of future clinical trials to cope with these
new mechanistic based drugs. There is very little overlap between
chapters and all are written by experts in the ﬁeld. Hundreds of
useful references are included for those wanting to go further.
My one and only problem was ﬁnding the colour prints tucked
away at the back. Maybe they were too expensive to include in
the text, but I found them eventually. Congratulations to the
editors as this must have been quite a task. Very good value for
$100 and essential reading for both the scientist and Ph.D. student.
Deﬁnitely one for the library to stock.
Paul Loadman
Cancer Research Unit
University of Bradford, UK
Corrigendum
Neuroblastoma in monozygotic twins – a case of probable twin
to twin metastasis
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The authors would like to acknowledge the Research into Child-
hood Cancer charity (Gibraltar) (RICC) for funding for the
above project.
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